NPPA approves price rise of 50 per cent for carbamazepine, ranitidine, ibuprofen

NPPA, in its meeting on June 28, deliberated upon the case of upward price revision of the formulations of these drugs under Para 19 of DPCO 2013 and noted that the scheduled formulations being considered for upward price revision are low-priced drugs and have been under repeated price controls, it added.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news